Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

antibody (1)

    displaying 1 - 3 records in total 3
    records per page




    The Coronavirus Disease Pandemic MESHD 2019 [COVID-19]: Impact on NHS England PET-CT Scanning 

    Authors: Wai Lup Wong; Peter Ross; Kevin Peters; Marion Frenz; Tong Hai; Alex Ridgeon; Ralph Toop; Peter Strouhal; Jimmy Bomanji

    doi:10.21203/rs.3.rs-77635/v1 Date: 2020-09-14 Source: ResearchSquare

    Purpose To examine the impact of the COVID-19 pandemic on PET-CT scanning activity across England.  Methods Monthly PET-CT scanning activity was collected from 41/48 NHS England provider sites. Data from 31/41sites was stratified by non-oncology/oncology and cancer type. Lung c ancer MESHDand lymphoma HP ymphoma MESHDactivity was split into specific indications. The data was compiled in Excel and analysed using Stata software to assess distribution and statistical significance of variation in activity comparing levels before and during the COVID-19 pandemic. Results In April and May 2020 a 32% and 31% decrease in activity was observed; a larger decrease for n on-cancer MESHDcompared with c ancer MESHDPET-CT. In June 2020 PET-CT activity started to recover with 6% fewer scans recorded compared with June 2019. Decrease and recovery varied according to c ancer MESHDtypes. Of the six most common indications for PET CT, l ung and oesophageal cancer MESHDhad the largest decrease in activity: lung -29%, -45% and oesophagus -43%, -59% in April and May respectively, and slowest recovery, -23%, -26% respectively in June. By contrast, lymphoma HP ymphoma MESHDand melanoma HP elanoma MESHDshowed the smallest decrease: lymphoma HP ymphoma MESHD-14%, -9%; melanoma HP elanoma MESHD-16%, +5% in April and May respectively, and fastest recovery +12% lymphoma HP ymphoma MESHD+14% respectively. Specifically, l ung cancer MESHDPET-CTs related to initial diagnosis and staging saw the largest fall HP and slowest recovery compared with PET-CTs for people with known l ung cancer. MESHD Conclusions There was considerable variation in the rate of decline and recovery in PET-CT scanning across c ancer MESHDtypes and specific indications related to the cancer type. The causes for the variation remain to be explained. 

    Augmentation of anti-MDA5 antibody SERO implies severe disease in COVID-19 patients

    Authors: Changzheng Liu; Qian Wang; Yeming Wang; Geng Wang; Linghang Wang; Hong Chen; Tao Jiao; Chaojun Hu; Xiaobo Lei; Li Guo; Lili Ren; Mengtao Li; Xiaofeng Zeng; Dingyu Zhang; Bin Cao; Jianwei Wang

    doi:10.1101/2020.07.29.20164780 Date: 2020-08-01 Source: medRxiv

    Recent studies have provided insights into the autoinflammation MESHD triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection MESHD, which is associated with high mortality of coronavirus disease MESHD 2019 (COVID-19). Striking similarities has been noted between COVID-19 and anti- melanoma HP melanoma MESHD differentiation-associated gene 5 (MDA5) antibody SERO (Ab)-related dermatomyositis MESHD ( DM MESHD), implying a shared autoinflammatory aberrance. However, it is unclear whether anti-MDA5 Ab is present in COVID-19 and correlates with the severity and adverse outcome of COVID-19 patients. Here, we found that the positive rate of anti-MDA5 Ab in patients with COVID-19 was 48.2% and the anti-MDA5 Ab positive patients tended to develop severe disease (88.6% vs 66.9%, P<0.0001). In particular, the titer of anti-MDA5 Ab was increased in the non-survivals (5.95{+/-}5.16 vs 8.22{+/-}6.64, P=0.030) and the positive rate was also higher than that in the survivals (23.5% vs 12.0%, P=0.012). Regarding to severe COVID-19 patients, we found that high titer of anti-MDA5 Ab ([≥]10.0 U/mL) was more prevalent in the non-survivals (31.2% vs 14.0%, P=0.006). Moreover, early profiling of anti-MDA5 Ab could distinguish severe patients from those with non-severe ones. Overall, our data reveal that anti-MDA5 Ab is prevalent in the COVID-19 patients and high titer of this antibody SERO is correlated with severe disease and unfavorable outcomes.

    Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation For Anti- Hypertensive Drug in Renal Cell Carcinoma MESHD Renal Cell Carcinoma HP

    Authors: Kihun Kim; Yeji Ko; Dai Sik Ko; Yun Hak Kim

    doi:10.21203/rs.3.rs-49602/v1 Date: 2020-07-27 Source: ResearchSquare

    Background: Owing to its worldwide spread, the coronavirus disease MESHD (COVID-19) epidemic was declared a pandemic by the World Health Organization on March 11, 2020. Angiotensin-converting enzyme 2 (ACE2) is the outer surface protein of the cell membrane that is abundantly distributed in the heart, lungs, and kidneys, and plays an important role in molecular docking of the severe acute respiratory syndrome coronavirus 2 MESHD. In this study, we aimed to analyze the difference in the survival rate according to ACE2 expressions in pan- cancer MESHD. Methods: The clinical and genomic data of pan- cancer MESHD patients were accessed from The cancer MESHD Genome Atlas. To identify the prognostic significance of ACE2, we used Kaplan-Meier with log-rank test, and the Cox proportional hazards regression to analyze prognostic significance. Results: In the Kaplan-Meier curve, clear cell renal cell carcinoma HP clear cell renal cell carcinoma MESHD ( ccRCC MESHD), uveal melanoma HP melanoma MESHD, and prostate adenocarcinoma MESHD showed statistically significant. In the Cox regression, thyroid carcinoma HP thyroid carcinoma MESHD and glioblastoma multiforme HP glioblastoma multiforme MESHD, and ccRCC MESHD showed significant results. Only ccRCC MESHD had statistically significant, and high ACE2 expression is related to good prognosis. Conclusions: It is known that ACE inhibitor, a primary antihypertensive agent, increases ACE2 expression. Based on these results, we believe that the ACE inhibitor will be important to increase the lifespan of ccRCC MESHD patients. This study is the first research to offer a recommendation on the use of anti- hypertensive MESHD drugs to ccRCC MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.